Prostate Cell News Volume 10.00 | Jan 11 2019

TOP STORY

Epigenetic Silencing of miRNA-338-5p and miRNA-421 Drives SPINK1-Positive Prostate Cancer

Ectopic expression of miRNA-338-5p/-421 in serine peptidase inhibitor, kazal type-1 (SPINK1)-positive cells abrogated oncogenic properties including cell-cycle progression, stemness and drug resistance, and showed reduced tumor burden and distant metastases in a mice model. [Clin Cancer Res] Abstract

(Ranked by impact factor of the journal)

An AR-ERG Transcriptional Signature Defined by Long Range Chromatin Interactomes in Prostate Cancer Cells

Scientists propose a novel framework to profile long-range chromatin interactions associated with androgen receptor (AR) and its collaborative transcription factor, erythroblast transformation-specific related gene (ERG), using chromatin interaction analysis by paired-end tag. [Genome Res] Abstract

AMPK Promotes SPOP-Mediated NANOG Degradation to Regulate Prostate Cancer Cell Stemness

The authors report that NANOG was degraded by SPOP, a frequently mutated tumor suppressor of prostate cancer (PCa). Cancer-associated mutations of SPOP or the mutation of NANOG at S68Y abrogated the SPOP-mediated NANOG degradation, leading to elevated PCa cancer stemness and poor prognosis. [Dev Cell] Full Article | Graphical Abstract

SPOP Promotes Nanog Destruction to Suppress Stem Cell Traits and Prostate Cancer Progression

Scientists report that SPOP suppresses stem cell traits of both embryonic stem cells and prostate cancer cells through promoting Nanog poly-ubiquitination and subsequent degradation. [Dev Cell] Full Article

Inhibition of De Novo Lipogenesis Targets Androgen Receptor Signaling in Castration-Resistant Prostate Cancer

Researchers developed an fatty acid synthase (FASN) inhibitor and demonstrated that selective FASN inhibition antagonized castration-resistant prostate cancer growth through metabolic reprogramming and resulted in reduced protein expression and transcriptional activity of both full-length androgen receptor (AR) and AR-variant V7. [Proc Natl Acad Sci USA] Full Article

Sumoylation of Flotillin-1 Promotes EMT in Metastatic Prostate Cancer by Suppressing Snail Degradation

Sumoylation of flotillin-1 by up-regulated UBC9 in human metastatic prostate cancer tissues and prostate cancer cells with high metastatic potential positively correlated with the stabilization of Snail and the induction of Snail-mediated epithelial-to-mesenchymal transition (EMT) genes in metastatic prostate cancer. [Oncogene] Full Article

Epigenetic Suppression of SERPINB1 Promotes Inflammation-Mediated Prostate Cancer Progression

Knockdown of highly expressed SERPINB1 in non-malignant prostatic epithelial cells increased proliferation, decreased apoptosis, and stimulated expression of epithelial-mesenchymal transition markers. [Mol Cancer Res] Abstract

Interactions with Muscle Cells Boost Fusion, Stemness, and Drug Resistance of Prostate Cancer Cells

Investigators explored interactions between prostate cancer and muscle cells that surround the prostate. They found that coculturing of prostate cancer cells with skeletal or smooth muscle cells expanded the subpopulations of cancer cells with features characteristic of cancer stem-like cells, including anchorage-independent growth, elevated CD133 expression, and drug resistance. [Mol Cancer Res] Abstract

Overexpression of SOCS3 Mediated by Adenovirus Vector in Mouse and Human Castration-Resistant Prostate Cancer Cells Increases the Sensitivity to NK Cells In Vitro and In Vivo

Scientists demonstrated that Ad-SOCS3 could significantly inhibit growth of castration-resistant prostate cancer (CRPC) cell lines expressing pSTAT3, DU-145, and TRAMP-C2, but not the PC-3 CRPC cell line with the STAT3 gene deleted. [Cancer Gene Ther] Abstract

Subscribe to one of our other 19 science newsletters such as Mammary Cell News & ESC & iPSC News.

Contribution of the Unfolded Protein Response to Breast and Prostate Tissue Homeostasis and Its Significance to Cancer Endocrine Response

The authors address the contribution of unfolded protein response (UPR) to breast and prostate tissues homeostasis and its significance to cancer endocrine response with focus on the current progress on UPR research related to cancer biology, detection, prognosis and treatment are also discussed. [Carcinogenesis] Abstract

Visit our reviews page to see a complete list of reviews in the prostate cell research field.

Nanobiotix and MD Anderson Cancer Center Announce a Large-Scale, Comprehensive Clinical Collaboration on NBTXR3

NANOBIOTIX and The University of Texas MD Anderson Cancer Center announced a large-scale, comprehensive clinical research collaboration to evaluate innovative strategies for treating patients with head and neck, pancreatic, thoracic, lung, gastrointestinal and genitourinary cancers. [NANOBIOTIX] Press Release

Harpoon Therapeutics Announces Preliminary Safety and Pharmacology Data from its HPN424 Phase I Trial in Prostate Cancer

Harpoon Therapeutics, Inc. announced preliminary safety and mechanism of action findings from an ongoing Phase I clinical trial evaluating its lead compound, HPN424, in patients with progressive metastatic castration resistant prostate cancer. [Harpoon Therapeutics, Inc.] Press Release

Arvinas Receives Authorization to Proceed for Its IND Application for PROTAC™ Therapy to Treat Patients with Metastatic Castration-Resistant Prostate Cancer

Arvinas, Inc. announced that the FDA has cleared the company’s investigational new drug application (IND) for ARV-110, an oral androgen receptor PROTAC™ protein degrader, for the treatment of patients with metastatic castration-resistant prostate cancer. [Arvinas, Inc.] Press Release

Department of Defense Awards CWRU Researcher Nearly $1M to Study Prostate Cancer Drug Resistance

Sanjay Gupta, PhD, of Case Western Reserve University (CWRU) School of Medicine and University Hospitals Cleveland Medical Center will receive $962,000 over three years to investigate drug resistance mechanisms in prostate cancer. [Case Western Reserve University] Press Release

Researchers Awarded $1 Million to Study Optimal Use of Radioactive Drugs for Prostate Cancer Therapy

Researchers at Weill Cornell Medicine, in collaboration with investigators at Dana-Farber Cancer Institute, have been awarded a three-year, $1 million grant from the U.S. Department of Defense for prostate cancer clinical trials. [Weill Cornell Medicine] Press Release

Northwestern Urology Program Receives $10M Gift from the Polsky Family to Create a Urologic Cancer Institute

Northwestern Medicine received a $10 million gift to fund the creation of a new multidisciplinary institute dedicated to urologic cancers. The Polsky Urologic Cancer Institute of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University at Northwestern Memorial Hospital will offer the most comprehensive approach to treating urologic cancers, including prostate, bladder, kidney and testicular cancers. [Northwestern Medicine] Press Release

Crowdfunding Research Flips Science’s Traditional Reward Model

No papers? No problem. Scientists who have historically been at a disadvantage when pursuing traditional funding sources — for example, those who lack extensive experience or who do not demonstrate a good publication record — are now the most successful at sourcing money from the public. [Nature News] Editorial

Serbia Is Rethinking Science — But the Reforms Could Cost Hundreds of Jobs

Serbia is making sweeping reforms to its ailing science system as part of its efforts to join the European Union — but some scientists say the changes could do more harm than good. [Nature News] Editorial

NEW 2019 ASCO Annual Meeting
May 31-June 4, 2019
Chicago, Illinois, United States

Visit our events page to see a complete list of events in the community.

NEW Postdoctoral Research Assistant – Prostate Cancer (AstraZeneca)

NEW Professorship – Molecular Mechanisms of Tumoral Diseases (Johann Wolfgang Goethe-University Frankfurt am Main)

NEW Senior Research Assistant – Cancer Biology (MD Anderson Cancer Center)

Postdoctoral Scientist – Prostate Oncobiology (Cancer Research Manchester Institute)

Faculty Position – Radiation Oncology & Molecular Radiation Sciences (Johns Hopkins University)

Research Fellow – Prostate Cancer Pathology (Weill Cornell Medicine)

Tenure-Track/Tenured Faculty Positions – Cancer Biology (University of Chicago)

Assistant Professor – Department of Integrative Biology & Pharmacology (University of Texas Health Science Center at Houston)

Faculty & Leadership Positions- Cancer-Focused Target & Drug Discovery (The University of New Mexico)

Postdoctoral Fellow – Cancer Immunotherapy (University of Notre Dame)

Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here.